Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

OBJECTIVE: This placebo-controlled study assessed long-term efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes and severe renal impairment (RI). RESEARCH DESIGN AND METHODS: In this 1-year, double-blind study, 133 patients with type 2 diabetes (H...

Descripción completa

Detalles Bibliográficos
Autores principales: McGill, Janet B., Sloan, Lance, Newman, Jennifer, Patel, Sanjay, Sauce, Christophe, von Eynatten, Maximilian, Woerle, Hans-Juergen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554278/
https://www.ncbi.nlm.nih.gov/pubmed/23033241
http://dx.doi.org/10.2337/dc12-0706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554278/
https://www.ncbi.nlm.nih.gov/pubmed/23033241
http://dx.doi.org/10.2337/dc12-0706

Ejemplares similares